GT201300154A - Comprimido farmaceutico de liberacion controlada para administracion oral - Google Patents

Comprimido farmaceutico de liberacion controlada para administracion oral

Info

Publication number
GT201300154A
GT201300154A GT201300154A GT201300154A GT201300154A GT 201300154 A GT201300154 A GT 201300154A GT 201300154 A GT201300154 A GT 201300154A GT 201300154 A GT201300154 A GT 201300154A GT 201300154 A GT201300154 A GT 201300154A
Authority
GT
Guatemala
Prior art keywords
oral administration
active principle
controlled liberation
compressed controlled
pharmaceutical compressed
Prior art date
Application number
GT201300154A
Other languages
English (en)
Inventor
Maria Angelica Arzola Paniagua
Hector Senosiain Arroyo
Gustavo Barranco Hernandez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46245166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201300154(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201300154A publication Critical patent/GT201300154A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPOSICIONES FARMACÉUTICAS EN FORMA DE COMPRIMIDOS PARA ADMINISTRACIÓN ORAL, QUE CONTIENEN PRINCIPIO ACTIVO Y EXCIPIENTES FARMACÉUTICAMENTE ACEPTABLES. LOS COMPRIMIDOS SE CARACTERIZAN PORQUE UNA PARTE DEL PRINCIPIO ACTIVO SE LIBERA EN FORMA INMEDIATA Y OTRA PARTE DEL PRINCIPIO ACTIVO SE ENCUENTRA EN UN SISTEMA MATRICIAL POLIMÉRICO Y DE DIFUSIÓN QUE PERMITE LIBERAR EL PRINCIPIO ACTIVO DE MANERA RETARDADA.
GT201300154A 2010-12-17 2013-06-17 Comprimido farmaceutico de liberacion controlada para administracion oral GT201300154A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2010014153A MX2010014153A (es) 2010-12-17 2010-12-17 Comprimido farmaceutico de liberacion controlada para administracion oral.

Publications (1)

Publication Number Publication Date
GT201300154A true GT201300154A (es) 2014-05-07

Family

ID=46245166

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201300154A GT201300154A (es) 2010-12-17 2013-06-17 Comprimido farmaceutico de liberacion controlada para administracion oral

Country Status (11)

Country Link
BR (1) BR112013014963A2 (es)
CL (1) CL2013001707A1 (es)
CO (1) CO6721021A2 (es)
CR (1) CR20130288A (es)
DO (1) DOP2013000136A (es)
EC (1) ECSP13012766A (es)
GT (1) GT201300154A (es)
MX (1) MX2010014153A (es)
PE (1) PE20140675A1 (es)
RU (1) RU2603469C2 (es)
WO (1) WO2012080984A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016058813A1 (en) 2014-10-16 2016-04-21 Koninklijke Philips N.V. Aligning a patient within an mr scanner

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL119627A (en) * 1996-11-17 2002-03-10 Yissum Res Dev Co PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED-RELEASE OF AN ACTIVE AGENT COMPRISING AT LEAST ONE β-LACTAM ANTIBIOTIC AGENT
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
EP1455751A1 (en) * 2001-12-20 2004-09-15 Pharmacia Corporation Zero-order sustained released dosage forms and method of making the same

Also Published As

Publication number Publication date
ECSP13012766A (es) 2013-09-30
BR112013014963A2 (pt) 2016-09-13
MX2010014153A (es) 2012-06-18
WO2012080984A2 (es) 2012-06-21
PE20140675A1 (es) 2014-06-25
CO6721021A2 (es) 2013-07-31
RU2603469C2 (ru) 2016-11-27
WO2012080984A3 (es) 2012-08-16
DOP2013000136A (es) 2013-10-15
CR20130288A (es) 2013-08-13
CL2013001707A1 (es) 2014-01-10
RU2013127408A (ru) 2015-01-27

Similar Documents

Publication Publication Date Title
CR11709A (es) Preparacion solida de desintegracion oral
MX2021000550A (es) Forma de dosis orales de liberacion sostenida de tofacitinib.
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
GT200600445A (es) Formas de presentación farmaceuticas solidas de administración oral con liberacion rapida del principio activo.
PE20142192A1 (es) Forma de dosificacion farmaceutica que comprende nifedipino o nisoldipino y un antagonista de angiotensina ii y/o diuretico
HK1218884A1 (zh) 用於在口腔中釋放至少種活性藥物成分的固體藥物劑型
IN2015DN03984A (es)
TN2015000135A1 (en) Modified release formulations for oprozomib
TN2011000651A1 (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine their preparation and their therapeutic application
WO2011111027A3 (en) Oral dispersible delayed release tablet formulation
PH12014501408A1 (en) Immediate release multi unit pellet system
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
MX2013013204A (es) Sistema de suministro de farmaco.
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida
JO3587B1 (ar) أشكال جرعات بينداموستين عن طريق الفم
AR068368A1 (es) Formas solidas de dosificacion de azitromicina de liberacion controlada
IT1401284B1 (it) Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
GT201300154A (es) Comprimido farmaceutico de liberacion controlada para administracion oral
TR201803451T4 (tr) Olmesartan formülasyonlari.
TN2015000156A1 (en) Dispersible tablet
UA105513C2 (uk) Лікарська форма уповільненого вивільнення глюкозаміну
IN2015MU00907A (es)
MX2015013279A (es) Forma de dosis orales de liberacion sostenida de tofacitinib.
CU20130165A7 (es) Liberación modificada de 4-metil-3-[[-4-(3- piridinil)-2-pirimidinil]amino]-n-5-(4- metil-1h-imidazol-1- il)-3- (trifluorometil) fenil] benzamida solubilizada utilizando acidos orgánicos